Pfizer Sees Neurontin Exclusivity Through 2002, Pregabalin Filing By Year-End
Pfizer expects at least 30 months of additional exclusivity for the epilepsy agent Neurontin (gabapentin) beyond the expiration of the basic compound patent July 15.
Pfizer expects at least 30 months of additional exclusivity for the epilepsy agent Neurontin (gabapentin) beyond the expiration of the basic compound patent July 15.